NCT04526912View on ClinicalTrials.gov

Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

May 19, 2021

Conditions
Acute Lung Injury
Interventions
DRUG

VIB7734

Single subcutaneous dose

DRUG

Placebo

Intravenous single dose matched to VIB7734.

Trial Locations (1)

44195

Research Site, Cleveland

Sponsors

Lead Sponsor

Viela Bio
All Listed Sponsors
lead

Viela Bio

INDUSTRY

NCT04526912 - Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection | Biotech Hunter | Biotech Hunter